HASS Corp
Hass Corp. manufactures and sells dental medical devices. Its CAD/CAM systems include Amber Mill, a machinable dental glass-ceramic blocks made of lithium disilicate; Amber Mill Direct, a CAD/CAM-based millable lithium disilicate block; Amber Mill H, a CAD/CAM block using nano-crystalline ceramics particle; Amber Mill Q, an implant abutment solution; and Amber Mill Meso, a lithium disilicate-base… Read more
HASS Corp (450330) - Net Assets
Latest net assets as of September 2025: ₩45.98 Billion KRW
Based on the latest financial reports, HASS Corp (450330) has net assets worth ₩45.98 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩56.06 Billion) and total liabilities (₩10.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩45.98 Billion |
| % of Total Assets | 82.01% |
| Annual Growth Rate | 80.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 75.34 |
HASS Corp - Net Assets Trend (2021–2024)
This chart illustrates how HASS Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HASS Corp (2021–2024)
The table below shows the annual net assets of HASS Corp from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩45.46 Billion | +200.02% |
| 2023-12-31 | ₩15.15 Billion | +38.26% |
| 2022-12-31 | ₩10.96 Billion | +42.19% |
| 2021-12-31 | ₩7.71 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to HASS Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 142.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩10.55 Billion | 23.20% |
| Common Stock | ₩3.92 Billion | 8.62% |
| Other Components | ₩30.99 Billion | 68.18% |
| Total Equity | ₩45.46 Billion | 100.00% |
HASS Corp Competitors by Market Cap
The table below lists competitors of HASS Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harbor Bankshares Corporation
PINK:HRBK
|
$11.51 Million |
|
US NeuroSurgical Holdings Inc
PINK:USNU
|
$11.51 Million |
|
Bioqual Inc
PINK:BIOQ
|
$11.52 Million |
|
Lucent, Inc.
OTCQB:LUCN
|
$11.52 Million |
|
Aplisens SA
WAR:APN
|
$11.51 Million |
|
The Brand House Collective, Inc.
NASDAQ:TBHC
|
$11.51 Million |
|
Hydrogen Freehold & Leasehold Real Estate Investment Trust
BK:HYDROGEN
|
$11.51 Million |
|
Ktop Reit
KO:145270
|
$11.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HASS Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,150,961,740 to 45,455,861,040, a change of 30,304,899,300 (200.0%).
- Net income of 1,791,316,210 contributed positively to equity growth.
- Share repurchases of 28,515,232,480 reduced equity.
- New share issuances of 28,515,232,480 increased equity.
- Other factors increased equity by 28,513,583,090.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.79 Billion | +3.94% |
| Share Repurchases | ₩28.52 Billion | -62.73% |
| Share Issuances | ₩28.52 Billion | +62.73% |
| Other Changes | ₩28.51 Billion | +62.73% |
| Total Change | ₩- | 200.02% |
Book Value vs Market Value Analysis
This analysis compares HASS Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.77x to 1.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩983.49 | ₩6660.00 | x |
| 2022-12-31 | ₩1398.45 | ₩6660.00 | x |
| 2023-12-31 | ₩1933.50 | ₩6660.00 | x |
| 2024-12-31 | ₩5800.89 | ₩6660.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HASS Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.08%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.21x
- Recent ROE (3.94%) is below the historical average (15.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 20.22% | 12.37% | 0.77x | 2.13x | ₩787.42 Million |
| 2022 | 24.12% | 17.73% | 0.79x | 1.73x | ₩1.55 Billion |
| 2023 | 11.85% | 11.20% | 0.55x | 1.93x | ₩280.63 Million |
| 2024 | 3.94% | 11.08% | 0.29x | 1.21x | ₩-2.75 Billion |
Industry Comparison
This section compares HASS Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $387,192,117,123
- Average return on equity (ROE) among peers: -96.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HASS Corp (450330) | ₩45.98 Billion | 20.22% | 0.22x | $11.51 Million |
| DIO Corporation (039840) | $194.43 Billion | 1.70% | 0.89x | $94.83 Million |
| Cellumed Co. Ltd (049180) | $5.18 Billion | -719.12% | 11.54x | $32.46 Million |
| SD Biosensor Inc (137310) | $2.20 Trillion | 48.32% | 0.36x | $174.83 Million |
| Dentium (145720) | $291.10 Billion | 19.06% | 0.96x | $192.13 Million |
| M.I.TECH Co.Ltd (179290) | $14.71 Billion | 4.08% | 0.17x | $45.98 Million |
| JETEMA Co. Ltd (216080) | $-5.04 Billion | 0.00% | 0.00x | $148.99 Million |
| Biodyne Co. Ltd. (314930) | $6.58 Billion | -30.82% | 2.54x | $144.24 Million |